Trial Profile
Prognostic factors in patients with recurrent small-cell lung cancer receiving amrubicin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2015
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Nov 2015 New trial record
- 30 Sep 2015 Results published in Tumori.